Meeting News
Advertisement
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Patients with MF or ET with CALR or JAK2 mutations carried similar symptom burdens according to prospective data.
The phase III MANIFEST-2 trial compared pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAKi-naive patients.
The findings were from a retrospective study of patient data from the US Flatiron Health electronic health record database.
Advertisement
A retrospective analysis covered two phase III trials of the JAK2 inhibitor in patients with and without monocytosis.
A study evaluated progression according to hemoglobin levels, platelet counts, constitutional symptoms, and other markers.
Patients in the cohort of a post-hoc analysis of the phase III CARTITUDE-4 trial received two different bridging regimens.
A retrospective study compared results from daratumumab plus carfilzomib plus dexamethasone in different lines of therapy.
Patients in the trial subanalysis had previously received an immunomodulatory agent, proteasome inhibitor, and daratumumab.
The review also compiled an array of proposed solutions to meet the needs of patients and caregivers.
Researchers identified several risk factors that predicted thrombosis in adults with ALL.
A study described how the implementation of tisa-cel has affected treatment outcomes in B-ALL.
MRD-negative CR status was able to predict long-term survival in newly diagnosed PH+ ALL.
Combining genomic markers and clinical parameters increased the accuracy of predicting treatment response in pediatric ALL.
The data herein supports the novel role of mutant CCR4 in enhancing T-cell lymphomagenesis and T-helper differentiation.
These highly encouraging data support further evaluation of epcoritamab.
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.